Evolution of Resistance During Clonal Expansion

Acquired drug resistance is a major limitation for cancer therapy. Often, one genetic alteration suffices to confer resistance to an otherwise successful therapy. However, little is known about the dynamics of the emergence of resistant tumor cells. In this article, we consider an exponentially growing population starting from one cancer cell that is sensitive to therapy. Sensitive cancer cells can mutate into resistant ones, which have relative fitness α prior to therapy. In the special case of no cell death, our model converges to the one investigated by Luria and Delbrück. We calculate the probability of resistance and the mean number of resistant cells once the cancer has reached detection size M. The probability of resistance is an increasing function of the detection size M times the mutation rate u. If Mu ≪ 1, then the expected number of resistant cells in cancers with resistance is independent of the mutation rate u and increases with M in proportion to \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(M^{1{-}1/\mathrm{{\alpha}}}\) \end{document} for advantageous mutants with relative fitness \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{{\alpha}}{>}1\) \end{document}, to \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{ln}M\) \end{document} for neutral mutants (α = 1), but converges to an upper limit for deleterious mutants (\batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{{\alpha}}{<}1\) \end{document}). Further, the probability of resistance and the average number of resistant cells increase with the number of cell divisions in the history of the tumor. Hence a tumor subject to high rates of apoptosis will show a higher incidence of resistance than expected on its detection size only.

[1]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Levy Antibiotic resistance: consequences of inaction. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[4]  Feller William,et al.  An Introduction To Probability Theory And Its Applications , 1950 .

[5]  Q Zheng,et al.  Progress of a half century in the study of the Luria-Delbrück distribution. , 1999, Mathematical biosciences.

[6]  B H Margolin,et al.  Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[8]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[9]  Martin A. Nowak,et al.  The role of chromosomal instability in tumor initiation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[11]  Martin A Nowak,et al.  Evolutionary dynamics of invasion and escape. , 2004, Journal of theoretical biology.

[12]  Lurias,et al.  MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .

[13]  William Feller,et al.  An Introduction to Probability Theory and Its Applications , 1967 .

[14]  B. Levin,et al.  Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. , 2000, Genetics.

[15]  M A Nowak,et al.  Antigenic diversity thresholds and the development of AIDS. , 1991, Science.

[16]  Douglas D. Richman,et al.  HIV chemotherapy , 2001, Nature.

[17]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[18]  R. Lenski,et al.  Bacterial evolution and the cost of antibiotic resistance. , 1998, International microbiology : the official journal of the Spanish Society for Microbiology.

[19]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[20]  M. Delbrück,et al.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance. , 1943, Genetics.

[21]  Steven A Frank,et al.  Somatic mosaicism and cancer: inference based on a conditional Luria-Delbrück distribution. , 2003, Journal of theoretical biology.

[22]  Martin A. Nowak,et al.  The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.

[23]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[24]  M A Nowak,et al.  Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.